XII Medical, which is developing neuromodulation therapy for patients with sleep apnea, said it plans to use the investment to increase its staff and enhance its technology and clinical research. The funding was led by venture capital firm Omega Funds and included Cleveland Clinic, a founding investor.
“Despite advancements in obstructive sleep apnea therapies, challenges remain that prevent millions of people from receiving adequate treatment,” Omega Funds senior associate Saoussen Ben Halima, PhD, said in an Aug. 21 statement. “We believe XII Medical developed a ground-breaking platform technology to simplify treatment, expand access and improve outcomes for patients.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
